









市場行情
/
股票
/
nasdaq-imvt
/

Immunovant Inc

IMVT

15.710USD

-0.370-2.30%

收盤 08/01, 16:00（美東）報價延遲15分鐘

2.67B總市值

虧損本益比TTM



Immunovant Inc

15.710

-0.370-2.30%

概覽公司財務

Immunovant, Inc. 是一家臨牀階段免疫學公司。該公司專注於開發自身免疫性疾病患者的治療方法。其產品線包括巴託利單抗和 IMVT-1402，這兩種都是新型的全人源單克隆抗體，靶向新生兒可結晶片段受體 (FcRn)。巴託利單抗是一種皮下注射劑。據觀察，巴託利單抗可降低引起炎症和疾病的免疫球蛋白 G (IgG) 抗體。其候選產品巴託利單抗採用小劑量給藥，並使用 27 號針頭。該公司正在開發用於治療重症肌無力 (MG)、甲狀腺眼病 (TED)、慢性炎症性脫髓鞘性多發性神經病 (CIDP) 和格雷夫斯病 (GD) 的巴託利單抗。其主要候選產品 IMVT-1402 還被觀察到在健康成人中進行的 I 期臨牀試驗中可降低 IgG 抗體水平。 IMVT-1402 是一種抑制 FcRn 的完全人源單克隆抗體。

公司簡介

公司代碼IMVT

公司名稱Immunovant Inc

上市日期May 14, 2019

成立日期2018

CEODr. Eric Venker, M.D.

員工數量362

證券類型Ordinary Share

年結日May 14

公司地址320 West 37Th Street

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編10018

電話19175803099

網址https://immunovant.com/

公司代碼IMVT

上市日期May 14, 2019

成立日期2018

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Frank M. Torti, M.D.

Executive Chairman of the Board

615.44K

-6.15%

Ms. Melanie Gloria

Chief Operating Officer

186.14K

+69.28%

Mr. Douglas J. Hughes

Independent Director

119.58K

-3.96%

Dr. Atul Pande, M.D.

Independent Director

95.41K

-14.51%

Mr. Andrew J. (Drew) Fromkin

Director

91.91K

-5.09%

Dr. Jay S. Stout, Ph.D.

Chief Technology Officer

81.19K

-5.06%

Dr. Michael Geffner, M.D.

Chief Medical Officer

44.95K

-7.31%

Mr. Jacob (Jake) Bauer

Independent Director

Mr. Robert G. Susman

Independent Director

Mr. Tiago Girao

Chief Financial Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Frank M. Torti, M.D.

Executive Chairman of the Board

615.44K

-6.15%

Ms. Melanie Gloria

Chief Operating Officer

186.14K

+69.28%

Mr. Douglas J. Hughes

Independent Director

119.58K

-3.96%

Dr. Atul Pande, M.D.

Independent Director

95.41K

-14.51%

Mr. Andrew J. (Drew) Fromkin

Director

91.91K

-5.09%

Dr. Jay S. Stout, Ph.D.

Chief Technology Officer

81.19K

-5.06%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

Roivant Sciences Ltd.

56.50%

Fidelity Management & Research Company LLC

9.42%

Deep Track Capital LP

5.55%

The Vanguard Group, Inc.

4.04%

T. Rowe Price Investment Management, Inc.

3.45%

Other

21.03%

持股股東

佔比

Roivant Sciences Ltd.

56.50%

Fidelity Management & Research Company LLC

9.42%

Deep Track Capital LP

5.55%

The Vanguard Group, Inc.

4.04%

T. Rowe Price Investment Management, Inc.

3.45%

Other

21.03%

股東類型

持股股東

佔比

Corporation

56.50%

Investment Advisor

27.03%

Hedge Fund

16.91%

Investment Advisor/Hedge Fund

7.34%

Research Firm

1.87%

Individual Investor

1.85%

Private Equity

1.66%

Sovereign Wealth Fund

0.37%

Pension Fund

0.26%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

493

195.12M

114.06%

-1.39M

2025Q1

505

194.81M

114.45%

+16.42M

2024Q4

482

163.29M

104.53%

-8.19M

2024Q3

464

162.18M

111.33%

-1.06M

2024Q2

453

157.67M

108.50%

+1.66M

2024Q1

433

151.47M

104.51%

-605.85K

2023Q4

420

150.13M

103.75%

+991.03K

2023Q3

373

143.75M

105.86%

+4.45M

2023Q2

335

132.11M

101.25%

-11.81M

2023Q1

333

135.44M

104.53%

-12.72M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Roivant Sciences Ltd.

96.65M

56.55%

Apr 21, 2025

Fidelity Management & Research Company LLC

16.12M

9.43%

+3.86M

+31.52%

Mar 31, 2025

Deep Track Capital LP

9.50M

5.56%

+3.50M

+58.33%

Mar 31, 2025

The Vanguard Group, Inc.

6.92M

4.05%

+251.99K

+3.78%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

5.89M

3.45%

+777.59K

+15.20%

Mar 31, 2025

Baker Bros. Advisors LP

5.46M

3.19%

+3.75M

+219.57%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.75M

2.78%

+191.44K

+4.20%

Mar 31, 2025

Armistice Capital LLC

4.50M

2.63%

+629.41K

+16.26%

Mar 31, 2025

State Street Global Advisors (US)

3.09M

1.81%

+389.57K

+14.44%

Mar 31, 2025

Perceptive Advisors LLC

2.84M

1.66%

+704.87K

+32.95%

Mar 31, 2025

持股ETF

更新時間: 14 小時前

機構名稱

佔比

Tema Neuroscience and Mental Health ETF

0.9%

Virtus LifeSci Biotech Clinical Trials ETF

0.9%

SPDR S&P Biotech ETF

0.43%

Invesco Nasdaq Biotechnology ETF

0.3%

ProShares Ultra Nasdaq Biotechnology

0.3%

Direxion Daily S&P Biotech Bull 3X Shares

0.25%

iShares Biotechnology ETF

0.11%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.07%

iShares Russell 2000 Growth ETF

0.07%

BNY Mellon US Small Cap Core Equity ETF

0.06%

Tema Neuroscience and Mental Health ETF

佔比0.9%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.9%

SPDR S&P Biotech ETF

佔比0.43%

Invesco Nasdaq Biotechnology ETF

佔比0.3%

ProShares Ultra Nasdaq Biotechnology

佔比0.3%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.25%

iShares Biotechnology ETF

佔比0.11%

JPMorgan BetaBuilders US Small Cap Equity ETF

佔比0.07%

iShares Russell 2000 Growth ETF

佔比0.07%

BNY Mellon US Small Cap Core Equity ETF

佔比0.06%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

KeyAI

